Literature DB >> 8873486

Human immunodeficiency virus type 1-related transient neurological deficits.

B J Brew1, J Miller.   

Abstract

PURPOSE: To characterize human immunodeficiency virus type 1 (HIV-1)-related transient neurological deficit (TND).
DESIGN: A 3-year prospective study based at a tertiary referral center.
METHODS: Patients with TND in the absence of an opportunistic infection, neoplasm, neurosyphilis, or seizure were recruited and further investigated. The frequency of hospital admission for these patients was compared with those who were HIV-1 seronegative and with those who were admitted for HIV-1-related thromboembolic events.
RESULTS: Twenty-seven patients were identified: mean age of 39 +/- 9 years; CD4+ cell count of 130 +/- 80/microL. Seven patients had no history of an AIDS-defining illness. Hemiparesis and hemisensory disturbance occurred in 23 patients (85%); 15 had preexisting ADC, 7 stage 1 and 8 stage 2; 3 developed ADC after 18 months. Thirteen patients had multiple attacks and 5 had more than 20; 2 patients developed a cerebral infarct. No cause for the TND was identified in 8 patients (30%). Anticardiolipin antibodies were found in 70% and low protein S levels in 53% which was significantly more often than in a neurologically normal group with similarly advanced HIV-1 disease. The frequency of admission was 0.8% whereas the frequency for similar TND in HIV-1-seronegative patients was 0.4% and the frequency for HIV-1-related thromboembolic events was 0.9%.
CONCLUSIONS: Transient neurological deficits occur in advanced HIV-1 disease and are often associated with ADC, elevated concentrations of anticardiolipin antibodies, and low protein S levels. Future studies will need to define the precise role of these associations in the pathogenesis of HIV-1-related TND.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8873486     DOI: 10.1016/S0002-9343(96)00123-4

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  7 in total

Review 1.  Infections and the antiphospholipid syndrome.

Authors:  Mario García-Carrasco; Claudio Galarza-Maldonado; Claudia Mendoza-Pinto; Ricardo O Escarcega; Ricard Cervera
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

Review 2.  The antiphospholipid syndrome and infection.

Authors:  G N Dalekos; K Zachou; C Liaskos
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

Review 3.  Role of Infectious Diseases in the Antiphospholipid Syndrome (Including Its Catastrophic Variant).

Authors:  Claudia Mendoza-Pinto; Mario García-Carrasco; Ricard Cervera
Journal:  Curr Rheumatol Rep       Date:  2018-08-20       Impact factor: 4.592

Review 4.  Cerebrovascular disease in HIV-infected individuals in the era of highly active antiretroviral therapy.

Authors:  Belinda Cruse; Lucette A Cysique; Romesh Markus; Bruce J Brew
Journal:  J Neurovirol       Date:  2012-04-14       Impact factor: 2.643

5.  Nonopportunistic neurologic manifestations of the human immunodeficiency virus: an Indian study.

Authors:  Alaka K Deshpande; Mrinal M Patnaik
Journal:  MedGenMed       Date:  2005-10-04

6.  Nonopportunistic neurologic manifestations of the human immunodeficiency virus: an Indian study.

Authors:  Alaka K Deshpande; Mrinal M Patnaik
Journal:  J Int AIDS Soc       Date:  2005-10-04       Impact factor: 5.396

7.  Central Nervous System Vasculopathy in HIV-Infected Children Enrolled in the Pediatric AIDS Clinical Trials Group 219/219C Study.

Authors:  John S Schieffelin; Paige L Williams; Divna Djokic; Jeffrey P Anderson; Sharon Nachman; James M Oleske; George R Seage; Russell B Van Dyke
Journal:  J Pediatric Infect Dis Soc       Date:  2012-10-26       Impact factor: 3.164

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.